BD, Quest Diagnostics Partner To Develop Companion Diagnostics For Cancer, Other Diseases
Portfolio Pulse from Benzinga Newsdesk
BD (Becton, Dickinson and Company) and Quest Diagnostics have announced a partnership to develop companion diagnostics for cancer and other diseases. The collaboration will include exploratory panel development and the manufacturing and distribution of FDA-approved diagnostic kits.
July 25, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BD (Becton, Dickinson and Company) has partnered with Quest Diagnostics to develop companion diagnostics for cancer and other diseases. This collaboration will enhance BD's product offerings and market reach in the healthcare diagnostics sector.
The partnership with Quest Diagnostics is likely to enhance BD's product portfolio and market presence in the healthcare diagnostics sector, potentially driving revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Quest Diagnostics has partnered with BD (Becton, Dickinson and Company) to develop companion diagnostics for cancer and other diseases. This collaboration will expand Quest's diagnostic capabilities and product offerings.
The partnership with BD is expected to expand Quest Diagnostics' capabilities and product offerings in the healthcare diagnostics market, potentially leading to increased revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100